by Jordana Choucair | Sep 30, 2022 | D.C. News
The Senate approved a continuing resolution to extend government funding through December 16. The bill renews the Food and Drug Administration (FDA) user fee agreement. From 2023 to 2027, the bill would allow the FDA to collect $1.78 billion to $1.9 billion in user...
by Jordana Choucair | Sep 30, 2022 | Life Sciences
The FDA approved Amylyx Pharmaceuticals Inc.’s ALS drug Relyvrio, the first treatment for Lou Gehrig’s disease that the agency has cleared in five years. Patient advocacy groups had pressured the FDA to approve the new treatment, though there’s still some...
by Jordana Choucair | Sep 30, 2022 | Mental Health
The House passed the Mental Health Matters Act by a largely party-line 220-205 vote. The bill would impose new fines on insurers that don’t follow federal mental health pay parity requirements. The legislation would also direct the Department of Education to...
by Jordana Choucair | Sep 30, 2022 | Mental Health
Provisional data from the Centers for Disease Control and Prevention (CDC) show that U.S. suicide rate rose in 2021 after two consecutive years of declines. In 2021, 47,646 people in the U.S. died by suicide, up from 45,979 in 2020. The four-percent increase...
by Jordana Choucair | Sep 30, 2022 | Providers
A federal judge ordered that the U.S. Department of Health and Human Services (HHS) must reinstate full 340B drug payments for the rest of 2022. Judge Rudolph Contreras’ ruling followed a Supreme Court decision in June that ordered HHS to pay providers for the smaller...
Recent Comments